More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes
Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.
More Cancer Mutations, Better Immunotherapy Outcomes
More Cancer Mutations, Better Immunotherapy Outcomes

Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

Immune checkpoint inhibitors are generally most effective against tumors with more genetic mutations, according to a new study, although the relationship isn’t true for all cancers.

pharma & biotech
Eli Lilly Will Buy Loxo Oncology for $8 BillionEli Lilly Will Buy Loxo Oncology for $8 Billion
Eli Lilly Will Buy Loxo Oncology for $8 Billion
Ashley Yeager | Jan 8, 2019
Loxo focuses on cancer treatments based on tumor genetics, which will contribute to Lilly’s push in the cancer drug space.
AI App Identifies Rare Genetic Disorders from Photos of Patients’ Faces
AI App Identifies Rare Genetic Disorders from Photos of Patients’ Faces
Catherine Offord | Jan 8, 2019
Deep-learning algorithms could help doctors narrow in on the causes of certain medical conditions, say researchers.
Former Taiwanese National Academy Head Cleared of Corruption
Former Taiwanese National Academy Head Cleared of Corruption
Ashley Yeager | Jan 3, 2019
Wong Chi-huey, who was the president of Academia Sinica until 2016, was found not guilty of taking bribes from a pharmaceutical company.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
2018 in Quotes
2018 in Quotes
Catherine Offord | Dec 24, 2018
From the effects of political upheaval on research to claims of gene-edited babies, the year has been a tumultuous one for the scientific community.
FDA Cracks Down on Purveyors of Stem Cell Treatments
FDA Cracks Down on Purveyors of Stem Cell Treatments
Ashley P. Taylor | Dec 21, 2018
The agency cites safety concerns with customers of Genetech who reported getting E. coli infections and sends letters to other stem cell companies reminding them to follow the rules.
Big Pharma Picks up on Medical Marijuana
Big Pharma Picks up on Medical Marijuana
Ashley P. Taylor | Dec 19, 2018
A Novartis subsidiary is partnering with a Canadian cannabis company to sell medical marijuana worldwide.
GlaxoSmithKline to Acquire Cancer Biotech TESARO for $5.1 Billion
GlaxoSmithKline to Acquire Cancer Biotech TESARO for $5.1 Billion
Carolyn Wilke | Dec 3, 2018
The purchase aims to build GSK’s oncology pipeline.
Data Sharing in Action: When Drug Companies Open Their Trial Vaults
Data Sharing in Action: When Drug Companies Open Their Trial Vaults
Abby Olena | Dec 3, 2018
YODA, a program facilitated by Yale University researchers, has successfully distributed clinical trial records from Johnson & Johnson and Medtronic to external researchers since 2013.